 
 
EXPLANATION:  CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW . 
        [Brackets ] indicate matter deleted from existing law.  
         Underlining  indicates amendments to bill.  
         Strike out  indicates matter stricken from the bill by amendment or deleted from the law by 
amendment.             *hb1131*      
HOUSE BILL 1131  
J1, F2    5lr2053  
      
By: Delegates Vogel and Tomlinson  
Introduced and read first time: February 5, 2025  
Assigned to: Health and Government Operations  
Committee Report: Favorable  
House action: Adopted  
Read second time: March 1, 2025  
 
CHAPTER ______  
 
AN ACT concerning  1 
 
Public Health  – Buprenorphine – Training Grant Program  and Workgroup  2 
 
FOR the purpose of establishing the Buprenorphine  Training Grant Program  to assist 3 
counties with offsetting the cost of training paramedics to administer buprenorphine; 4 
including the Program as an authoriz ed use of funding from the Opioid Rest itution  5 
Fund;  requiring the Maryland Office of Overdose Response to convene  a workgroup 6 
to study access to  buprenorphine in the State; and gen erally relating to 7 
buprenorphine.  8 
 
BY adding to  9 
 Article – Health – General  10 
Section 13 –5501 and 13 –5502  to be under the new subtitle “Subtitle 55. 11 
Buprenorphine Trainin g Grant Program”  12 
 Annotated Code of Maryland  13 
 (2023 Replacement Volume and 2024 Supplement)  14 
 
BY repealing and reenacting, without amendments,  15 
 Article – State Finance and Procurement  16 
 Section 7 –331(a) through (e)  17 
 Annotated Code of Maryland  18 
 (2021 Replacement Volume and 2024 Supplement)  19 
 
BY repealing and reenacting, with amendments,  20 
 Article – State Finance and Procurement  21 
 Section 7 –331(f) 22 
2 HOUSE BILL 1131   
 
  Annotated Code of Maryland  1 
 (2021 Replacement Volume and 2024 Supplement)  2 
 
 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 3 
That the Laws of Maryland read as follows:  4 
 
Article – Health  – General  5 
 
SUBTITLE 55. BUPRENORPHINE TRAINING GRANT PROGRAM . 6 
 
13–5501. 7 
 
 (A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE  THE MEANINGS 8 
INDICATED . 9 
 
 (B) “PARAMEDIC ” HAS  THE MEANING STATED I N § 13–516 OF THE 10 
EDUCATION ARTICLE . 11 
 
 (C) “PROGRAM ” MEANS THE BUPRENORPHINE TRAINING GRANT 12 
PROGRAM . 13 
 
13–5502.  14 
 
 (A) (1) THERE IS A BUPRENORPHINE TRAINING GRANT PROGRAM IN 15 
THE DEPARTMENT . 16 
 
  (2) THE PURPOSE OF THE PROGRAM IS TO  ASSIST  A COUNT Y WITH 17 
OFFSETTING THE COST OF TRAINING PARAMEDI CS TO ADMINISTER 18 
BUPRENORPHINE . 19 
 
 (B) A COUNTY MAY APPLY TO THE DEPARTMENT  FOR A GRANT FROM THE  20 
PROGRAM . 21 
 
 (C) A COUNTY MAY USE A GRA NT AWARDED UNDER THE PROGRAM  ONLY 22 
FOR TRAINING PARAMED ICS TO ADMINISTER BUPRENORPHINE .  23 
 
 (D) THE GOVERNOR SHALL INCLUDE IN THE ANNUA L BUDGET BILL AN  24 
APPROPRIATION OF AT LEAST $50,000  FROM THE  OPIOID RESTITUTION FUND FOR 25 
THE PROGRAM .  26 
 
Article – State Finance and Procurement  27 
 
7–331. 28 
 
 (a) In this section, “Fund” means the Opioid Restitution Fund.  29 
 HOUSE BILL 1131  3 
 
  
 (b) There is an Opioid Restitution Fund.  1 
 
 (c) The purpose of the Fund is to retain the amount of settlement revenues 2 
deposited to the Fund in accordance with subsection (e)(1) of this sect ion. 3 
 
 (d) (1) The Fund is a special, nonlapsing fund that is not subject to § 7 –302 of 4 
this subtitle.  5 
 
  (2) The State Treasurer shall hold the Fund separately, and the 6 
Comptroller shall account for the Fund.  7 
 
 (e) The Fund consists of:  8 
 
  (1) all revenue s received by the State from any source resulting, directly or 9 
indirectly, from any judgment against, or settlement with, opioid manufacturers, opioid 10 
research associations, or any other person in the opioid industry relating to any claims 11 
made or prosecut ed by the State to recover damages for violations of State law; and  12 
 
  (2) the interest earnings of the Fund.  13 
 
 (f) The Fund may be used only to provide funds for:  14 
 
  (1) programs, services, supports, and resources for evidence –based 15 
substance use disorder  prevention, treatment, recovery, or harm reduction that have the 16 
purpose of:  17 
 
   (i) improving access to medications proven to prevent or reverse an 18 
overdose, including by supporting the initiative to co –locate naloxone with automated 19 
external defibrillat ors placed in public buildings under § 13 –518 of the Education Article;  20 
 
   (ii) supporting peer support specialists and screening, brief 21 
intervention, and referral to treatment services for hospitals, correctional facilities, and 22 
other high –risk populatio ns; 23 
 
   (iii) increasing access to medications that support recovery from 24 
substance use disorders;  25 
 
   (iv) expanding the Heroin Coordinator Program, including for 26 
administrative expenses;  27 
 
   (v) expanding access to crisis beds and residential treatment 28 
services for adults and minors;  29 
 
   (vi) expanding and establishing safe stations, mobile crisis response 30 
systems, and crisis stabilization centers;  31 
 
4 HOUSE BILL 1131   
 
    (vii) supporting the behavioral health crisis hotline;  1 
 
   (viii)  organizing primary and secondary school education campaigns 2 
to prevent opioid use, including for administrative expenses;  3 
 
   (ix) enforcing the laws regarding opioid prescriptions and sales, 4 
including for administrative expenses;  5 
 
   (x) research regarding and training for substance use treatment and 6 
overdose prevention, including for administrative expenses; and  7 
 
   (xi) supporting and expanding other evidence –based interventions 8 
for overdose prevention and substance use treatment;  9 
 
  (2) supporting community –based nonprofit recovery org anizations that 10 
provide nonclinical substance use recovery support services in the State;  11 
 
  (3) evidence –informed substance use disorder prevention, treatment 12 
recovery, or harm reduction pilot programs or demonstration studies that are not  13 
evidence –based if the Opioid Restitution Fund Advisory Council, established under §  14 
7.5–902 of the Health – General Article:  15 
 
   (i) determines that emerging evidence supports the distribution of 16 
money for the pilot program or that there is a reasonable b asis for funding the 17 
demonstration study with the expectation of creating an evidence –based program; and  18 
 
   (ii) approves the use of money for the pilot program or demonstration 19 
study; [and] 20 
 
  (4) evaluations of the effectiveness and outcomes reporting f or substance 21 
use disorder abatement infrastructure, programs, services, supports, and resources for 22 
which money from the Fund was used, including evaluations of the impact on access to 23 
harm reduction services or treatment for substance use disorders and th e reduction in 24 
drug –related mortality ; AND  25 
 
  (5) THE BUPRENORPHINE TRAINING GRANT PROGRAM 26 
ESTABLISHED UNDER § 13–5502  OF THE HEALTH – GENERAL ARTICLE . 27 
 
 SECTION 2. AND BE IT FURTHER ENACTED, That:  28 
 
 (a) The Maryland Office of Overdose Response shall convene a  workgroup to 29 
study  access to  buprenorphine in the State.  30 
 
 (b) The workgroup shall include:  31 
 
  (1) one member of the Senate  of Maryland, appointed by the  President of 32 
the Senate ; 33 
 HOUSE BILL 1131  5 
 
  
  (2) one member of the House of Delegates , appointed by the Speak er of the 1 
House ; and 2 
 
  (3) representatives of : 3 
 
   (i) the Maryland Institute of Emergency Medical Services Systems;  4 
 
   (ii) the Behavioral Health Administration;  5 
 
   (iii) hospitals;  6 
 
   (iv) local behavioral health agencies; and  7 
 
   (v) the Maryland Association of Counties.  8 
 
 (c) The workgroup shall examine:  9 
 
  (1) how buprenorphine services are offered in the State;  10 
 
  (2) the capacity of providers to provide buprenorphine ;  11 
 
  (3) any geographic areas where significant gaps in buprenorphine services  12 
may exist;  13 
 
  (4) the feasibility of financial support for a long –term expansion of 14 
buprenorphine services;  15 
 
  (5) a plan for ongoing data collection for the purpose of the monitoring and 16 
improvement of buprenorphine services;  17 
 
  (6) how to effectively grow a hub –and–spoke model to ensure access to 18 
buprenorphine in the State ; and  19 
 
  (7) any other strategies that would improve buprenorphine services  in the 20 
State .  21 
 
 (d) On or before December 31, 2025, the Maryland Office of Overdose Response 22 
shall submit a report on the findings and recommendations of the workgroup, including the 23 
need for any statutory changes , to the Governor  and, in accordance with § 2 –1257 of the 24 
State Government Article , the Senate Finance Committee and the  House Health an d 25 
Government Operations Committee.  26 
 
 SECTION 3. AND BE IT FURTHER ENACTED, That Section 1 of this Act shall take 27 
effect October 1, 2025.  Section 1 of this Act shall remain in effect for a period of 5 years and, 28 
at the end of September 30, 2030, Section 1 of this Act, with no further action required by 29 
the General Assembly, shall be abrogated and of no further force and effect.  30 
6 HOUSE BILL 1131   
 
  
 SECTION 4. AND BE IT FURTHER ENACTED, That , except as provided in Section 1 
3 of this Act,  this Act shall take effect July 1, 2025.  Section 2 of this Act  shall remain 2 
effective for a period of 1 year and, at the end of  June 30, 202 6, Section 2 of this Act, with 3 
no further action required by the General Assembly, shall be abrogated and of no further 4 
force and effect.  5 
 
 
 
Approved:  
________________________________ ________________________________ ________________   
           Governor.  
________________________________ ________________________________ ________________   
         Speaker of the House of Delegates.  
________________________________ ________________________________ ________________   
                 President of the Senate.  